MountainView Hospital and Sarah Cannon, the Cancer Institute of HCA Healthcare, recently celebrated its 50th blood and marrow transplant case in Las Vegas. The milestone transplant comes two years after the program’s inception.
The Sarah Cannon Transplant & Cellular Therapy Program at MountainView Hospital is the only such program in the state of Nevada and has received internationally-recognized accreditation by the Foundation for the Accreditation of Cellular Therapy (FACT) for adult autologous transplantation and immune effector cell therapy (IECT).
Prior to the opening of the new service at MountainView, 100 percent of patients had to leave Nevada to seek these services. Patients now have the option to receive this specialized care close to home.
Patients with blood cancers such as leukemia, lymphoma or multiple myeloma may be recommended by their physician to undergo a blood and marrow transplant, which is sometimes referred to as a stem cell transplant or bone marrow transplant.
“This milestone is significant because it means that 50 members of our community were able to receive care close to home, rather than leave the state for this care,” said Hiral Patel, MountainView’s Chief Executive Officer. “Since our launch we have been able to offer the complete continuum of care for blood-related malignancies here in Las Vegas and will continue to grow the program to provide safe, quality care to our patients with complex blood cancers.”
Prior to the opening of the BMT program at MountainView, approximately 100 Nevada residents per year had to leave the state to obtain blood and marrow transplant care which can create financial burdens and add unnecessary stress to the patient and their family. In bringing this complex care to the Nevada community, cost and burden to patients can be reduced while providing the most cutting-edge services close to home.
Dr. Delva Deauna-Limayo serves as the medical director for the Sarah Cannon Transplant & Cellular Therapy Program at MountainView Hospital.
“Following our FACT accreditation this year, caring for 50 patients is a significant milestone as we care for our community and grow the program,” said Dr. Deauna-Limayo. “We are also grateful for the partnership with our community oncologists that allow us to keep their patients close to home for this specialized care.”
According to Dr Navneet Majhail, Physician-in-Chief of Blood Cancers at Sarah Cannon: “I would like to congratulate our team at MountainView on their 50th transplant. It is significant because it allows patients from Nevada access to care close to home. With the clinical pathways and support the program receives from the Sarah Cannon Transplant and Cellular Therapy Network, patients can expect the same high-quality care they would receive at any of our programs across the country.”
The Sarah Cannon Transplant & Cellular Therapy Program at MountainView Hospital is part of the Sarah Cannon Transplant & Cellular Therapy Network, offering patients convenient, community-based access to complex blood cancer care including acute leukemia, blood and marrow transplantation, clinical trials and innovative therapies. The Network treats 1,600+ transplant and cellular therapy patients annually across its ten FACT/JACIE accredited programs in the United States and United Kingdom.